The technology is said to be twice as accurate at predicting five-year cancer risk compared to current risk assessment methods.

Giving colchicine to patients prior to TAVR may reduce the risk of certain conduction disturbances, according to new research published in the Journal of the American Heart Association. It does not, however, improve survival.

Experts are hopeful their device can address some of the shortcomings of currently used shielding methods.